RVL Pharmaceuticals plc (OSMT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
RVL Pharmaceuticals plc (OSMT) trades at $1.11 with AI Score 50/100 (Grade B). RVL Pharmaceuticals plc (OSMT) is an integrated biopharmaceutical company focused on developing and commercializing pharmaceutical products. Market cap: $110M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for OSMT: OSMT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OSMT against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OSMT: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
RVL Pharmaceuticals plc (OSMT) Healthcare & Pipeline Overview
RVL Pharmaceuticals plc (OSMT) is a biopharmaceutical company specializing in developing and commercializing treatments for neurological disorders, ophthalmic conditions, and women's health. With a focus on extended-release formulations and novel therapies, RVL serves markets in the United States, Argentina, and Hungary, facing competition in the biotechnology sector.
What Is the Investment Thesis for OSMT?
RVL Pharmaceuticals plc presents a speculative investment opportunity within the biopharmaceutical sector. The company's diverse product portfolio, including both promoted and non-promoted drugs, provides multiple revenue streams. Key value drivers include the successful commercialization of Upneeq for Blepharoptosis and the advancement of Arbaclofen ER through Phase III clinical trials. The company's gross margin of 81.0% indicates strong pricing power. However, the company's negative profit margin of -104.0% raises concerns about profitability. Upcoming catalysts include the potential FDA approval of Arbaclofen ER and the continued market penetration of Upneeq. Potential risks include clinical trial failures, regulatory hurdles, and intense competition in the pharmaceutical market.
Based on FMP financials and quantitative analysis
OSMT Key Highlights
Market capitalization of $110M, indicating a small-cap company with potential for growth but also higher volatility.
- Gross margin of 81.0%, suggesting efficient cost management in the production and sales of its pharmaceutical products.
- Negative profit margin of -104.0%, highlighting significant challenges in achieving profitability despite a high gross margin.
- Beta of 1.96, indicating higher volatility compared to the overall market, which may attract risk-tolerant investors.
- Focus on developing and commercializing treatments for neurological disorders, ophthalmic conditions, and women's health, addressing significant unmet medical needs.
Who Are OSMT's Competitors?
OSMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals plc | $250.65 | -0.60% | $15.7B | 58 |
| TEVA Teva Pharmaceutical Industries Limited | $37.47 | +2.43% | $43.6B | 44 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OSMT's Key Strengths?
Diverse product portfolio targeting multiple therapeutic areas.
- High gross margin of 81.0%, indicating strong pricing power.
- Focus on extended-release formulations and novel therapies.
- Established presence in the United States, Argentina, and Hungary.
What Are OSMT's Weaknesses?
Negative profit margin of -104.0%, indicating significant profitability challenges.
- High beta of 1.96, indicating higher volatility compared to the market.
- Reliance on regulatory approvals for new product launches.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive OSMT Stock Higher?
Potential FDA approval of Arbaclofen ER for the treatment of multiple sclerosis spasticity.
- Continued market penetration and sales growth of Upneeq for Blepharoptosis.
- Results from Phase I clinical trials for OS870 in neurodegenerative disorders.
- Strategic partnerships and acquisitions to expand product portfolio.
What Are the Key Risks for OSMT?
Financial-distress signal — its Altman Z-Score of -8.04 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-80.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for Arbaclofen ER or OS870.
- Regulatory setbacks or delays in obtaining FDA approvals.
- Intense competition from larger pharmaceutical companies.
- Patent expirations and generic competition for existing products.
- Economic downturns and changes in healthcare policies impacting demand for RVL's products.
What Are the Growth Opportunities for OSMT?
- Expansion of Upneeq Market: Upneeq, RVL's oxymetazoline hydrochloride ophthalmic solution for Blepharoptosis, represents a significant growth opportunity. The market for non-surgical aesthetic treatments is expanding, with a growing demand for solutions like Upneeq. RVL can capitalize on this trend through targeted marketing campaigns and strategic partnerships with ophthalmologists and dermatologists. The global eye care market is projected to reach $190 billion by 2028, providing a substantial addressable market for Upneeq.
- Advancement of Arbaclofen ER: Arbaclofen extended-release tablets, currently in Phase III clinical trials for the treatment of multiple sclerosis spasticity, offer a substantial growth opportunity. If approved, Arbaclofen ER could address a significant unmet need in the treatment of MS spasticity. The global multiple sclerosis drugs market is projected to reach $30 billion by 2027. Successful completion of clinical trials and subsequent FDA approval would drive significant revenue growth for RVL.
- Development of OS870: RVL's OS870, currently in Phase I clinical trials for neurodegenerative disorders, represents a long-term growth opportunity. The market for neurodegenerative disease treatments is expanding, driven by an aging population and increasing prevalence of conditions such as Alzheimer's and Parkinson's disease. Successful development and commercialization of OS870 could position RVL as a key player in this market. The global neurodegenerative disease market is projected to reach $45 billion by 2028.
- Strategic Acquisitions and Partnerships: RVL can pursue strategic acquisitions and partnerships to expand its product portfolio and pipeline. Collaborating with other pharmaceutical companies or acquiring complementary assets can accelerate growth and diversify revenue streams. This strategy can also provide access to new technologies and markets. The pharmaceutical industry is characterized by frequent mergers and acquisitions, providing ample opportunities for RVL to pursue this growth strategy.
- Geographic Expansion: RVL currently operates in the United States, Argentina, and Hungary. Expanding into new geographic markets, particularly in Europe and Asia, represents a significant growth opportunity. These markets offer substantial potential for RVL's existing products and pipeline candidates. Successful geographic expansion would require strategic partnerships, regulatory approvals, and targeted marketing efforts. The global pharmaceutical market is projected to reach $1.5 trillion by 2028, highlighting the potential for international growth.
What Are OSMT's Competitive Advantages?
- Proprietary Formulations: RVL's focus on developing extended-release formulations provides a competitive advantage. These formulations offer improved patient compliance and convenience, differentiating RVL's products from generic alternatives.
- Patent Protection: RVL's pharmaceutical products are protected by patents, providing a period of market exclusivity. This patent protection allows RVL to generate higher profits and recoup its investment in research and development.
- Established Brands: RVL has established brands such as Upneeq, which enjoy strong recognition and customer loyalty. These brands provide a competitive advantage and support pricing power.
- Regulatory Expertise: RVL has developed expertise in navigating the complex regulatory approval process for pharmaceutical products. This expertise provides a competitive advantage and reduces the risk of delays or rejection.
What Does OSMT Do?
Osmotica Pharmaceuticals plc, now known as RVL Pharmaceuticals plc, was founded with the goal of developing and commercializing innovative pharmaceutical products. The company focuses on addressing unmet medical needs across various therapeutic areas, including neurology, ophthalmology, and women's health. RVL's product portfolio includes both promoted and non-promoted products. Promoted products include M-72 (methylphenidate hydrochloride extended-release tablets) for ADHD, Osmolex ER (amantadine extended-release tablets) for Parkinson's disease and drug-induced extrapyramidal reactions, Arbaclofen extended-release tablets (currently in Phase III clinical trials) for multiple sclerosis spasticity, and Upneeq (oxymetazoline hydrochloride ophthalmic solution) for Blepharoptosis. Additionally, RVL is developing OS870, a product in Phase I clinical trials for neurodegenerative disorders. The company also offers women's health products such as Divigel for menopause and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. RVL's non-promoted products include methylphenidate ER tablets for ADHD, venlafaxine ER tablets for major depressive and social anxiety disorders, hydromorphone ER for pain, nifedipine ER for hypertension, sodium benzoate/sodium phenylacetate for hyperammonemia, oxybutynin ER for overactive bladder, prescription prenatal vitamins, Lorzone for acute musculoskeletal pain, ConZip for pain management, and nitrofurantoin for urinary tract infections. The company is headquartered in Bridgewater, New Jersey, and operates in the United States, Argentina, and Hungary.
What Products and Services Does OSMT Offer?
- Develop and commercialize pharmaceutical products.
- Focus on treatments for neurological disorders, including ADHD and Parkinson's disease.
- Offer solutions for ophthalmic conditions, such as Blepharoptosis.
- Provide women's health products, including treatments for menopause and prenatal supplements.
- Conduct clinical trials to advance new drug candidates.
- Market and sell both promoted and non-promoted pharmaceutical products.
- Operate in the United States, Argentina, and Hungary.
How Does OSMT Make Money?
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture or contract manufacture pharmaceutical products.
- Market and sell pharmaceutical products through a sales force and distribution network.
- Generate revenue from product sales.
What Industry Does OSMT Operate In?
RVL Pharmaceuticals plc operates in the competitive biotechnology industry, characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for neurological disorders, ophthalmic conditions, and women's health products is substantial and growing, driven by an aging population and increasing awareness of treatment options. RVL competes with both large pharmaceutical companies and smaller biotech firms. Success in this industry requires innovation, effective marketing, and strategic partnerships.
Who Are OSMT's Key Customers?
- Patients with neurological disorders, such as ADHD and Parkinson's disease.
- Patients with ophthalmic conditions, such as Blepharoptosis.
- Women seeking treatments for menopause and prenatal care.
- Healthcare providers who prescribe and recommend RVL's products.
- Pharmacies and distributors that stock and sell RVL's products.
Earnings Track Record
RVL Pharmaceuticals plc has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 221.2% below estimates on average.
OSMT Valuation & Market Position
With a $110M market cap, RVL Pharmaceuticals plc sits in the micro-cap segment of the market. Relative to its peer group, OSMT's quantitative score of 50/100 is below the peer average of 66/100.
Key Financial Metrics
Return on equity for RVL Pharmaceuticals plc stands at -80.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.2%, showing how much profit it generates from its asset base. A current ratio of 2.89 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
RVL Pharmaceuticals plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.04 places it in the distress zone, a signal of elevated financial risk.
Company Profile
RVL Pharmaceuticals plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bridgewater, US. The company is led by CEO Brian Markison. OSMT has traded publicly since 2018.
OSMT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in RVL Pharmaceuticals' future prospects, indicating that key stakeholders believe in the company's growth potential.
- Community sentiment has shifted positively, with discussions highlighting RVL's innovative product pipeline and its potential to address unmet medical needs.
- Analysts have noted recent partnerships that could enhance market reach and operational capabilities, bolstering investor optimism.
- The overall healthcare sector has shown resilience, and RVL's positioning within it could capitalize on broader market trends favoring pharmaceutical advancements.
Bear Case
- Concerns about regulatory hurdles have emerged, as the pharmaceutical industry often faces scrutiny that can delay product launches and impact revenue.
- Social sentiment reveals skepticism regarding the company's ability to compete with larger players in the market, raising doubts about long-term sustainability.
- Recent earnings reports have not met market expectations, leading to increased caution among investors and analysts alike.
- Community discussions indicate a lack of clarity regarding the company's strategic direction, which could hinder investor confidence and market performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OSMT Latest News
No recent news available for OSMT.
OSMT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OSMT.
Price Targets
Wall Street price target analysis for OSMT.
OSMT MoonshotScore
What does this score mean?
The MoonshotScore rates OSMT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Brian Markison
CEO
Brian Markison has extensive experience in the pharmaceutical industry, with a proven track record of leading and growing successful companies. Prior to joining RVL Pharmaceuticals plc, he held leadership positions at King Pharmaceuticals and Fougera Pharmaceuticals. His expertise spans commercial operations, strategic planning, and business development. Markison's background includes a strong focus on sales and marketing, as well as a deep understanding of the regulatory landscape.
Track Record: Under Brian Markison's leadership, RVL Pharmaceuticals plc has focused on expanding its product portfolio and advancing its pipeline of drug candidates. Key milestones include the commercial launch of Upneeq and the progression of Arbaclofen ER through Phase III clinical trials. Markison has also overseen strategic initiatives to improve operational efficiency and strengthen the company's financial position.
What Investors Ask About RVL Pharmaceuticals plc (OSMT) — Healthcare
What does the AI Score mean for OSMT?
OSMT holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. RVL Pharmaceuticals plc (OSMT) is an integrated biopharmaceutical company focused on developing and commercializing pharmaceutical products. The company's portfolio includes treatments for ADHD …
What does RVL Pharmaceuticals plc do?
RVL Pharmaceuticals plc is an integrated biopharmaceutical company that develops and commercializes pharmaceutical products, primarily focusing on treatments for neurological disorders, ophthalmic conditions, and women's health. Its key products include Upneeq for Blepharoptosis, Osmolex ER for Parkinson's disease, and Arbaclofen ER (currently in Phase III trials) for multiple sclerosis spasticity.
What do analysts say about OSMT stock?
Analyst coverage of RVL Pharmaceuticals plc (OSMT) is limited, reflecting its small-cap status and speculative nature. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's current lack of profitability. Growth considerations center on the successful commercialization of Upneeq and the advancement of Arbaclofen ER through clinical trials.
What are the main risks for OSMT?
RVL Pharmaceuticals plc faces several key risks, including clinical trial failures, regulatory setbacks, and intense competition from larger pharmaceutical companies. The company's reliance on regulatory approvals for new product launches exposes it to potential delays or rejection. Patent expirations and generic competition could erode sales of existing products.
What are the key factors to evaluate for OSMT?
RVL Pharmaceuticals plc (OSMT) holds an AI score of 50/100 (moderate). RVL Pharmaceuticals plc presents a speculative investment opportunity within the biopharmaceutical sector. Not financial advice.
How frequently does OSMT data refresh on this page?
OSMT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OSMT's recent stock price performance?
RVL Pharmaceuticals plc (OSMT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio targeting multiple therapeutic areas. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OSMT overvalued or undervalued right now?
RVL Pharmaceuticals plc (OSMT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OSMT before investing?
Before investing in RVL Pharmaceuticals plc (OSMT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Financial data may be subject to change.
- Analyst opinions may vary.